PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026Clinical Cancer Research0 citations

Shaping the future of HER2-directed therapy in biliary tract cancer

View Full Paper
ÓFÓrla FitzpatrickJHJames J. Harding

Key Points

  • To discuss HER2 testing and therapy resistance in HER2 positive biliary tract cancer.
  • Reviewed a retrospective study of HER2 positive biliary tract cancer patients.
  • Evaluated testing criteria for HER2 with next generation sequencing and immunohistochemistry.
  • Discussed potential roles of HER2 in prognosis and therapy.
  • Identified discrepancies between next generation sequencing and HER2 immunohistochemistry results.
  • Highlighted the need for standardized HER2 testing criteria.
  • Noted the importance of understanding therapeutic resistance mechanisms for HER2 targeted therapies.

Abstract

Abstract This commentary on a retrospective study of patients with HER2 positive biliary tract cancer highlights the importance of reflex and validated HER2 testing criteria; the discordance of next generation sequencing and HER2 immunohistochemistry; the potential prognostic and predictive role of HER2; and the necessity to define HER2 therapy resistance mechanisms.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Fitzpatrick et al. (2026) studied this question.

synapsesocial.com/papers/69994cb3873532290d02151bhttps://doi.org/10.1158/1078-0432.ccr-25-4464
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HER2 in Metastatic Colorectal Cancer: Diagnostic and Therapeutic Opportunities and Challenges2026
  2. 2Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer2026 · 1 citations
  3. 3Advances in Targeting HER2 across Cancer Subtypes – A Pan-tumor Approach2025
  4. 4Advances in Targeting HER2 across Cancer Subtypes – A Pan-tumor Approach2025
  5. 5Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer—A Single-Center Experience2024 · 1 citations